GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xeris Biopharma Holdings XERS · USD

Health Care · US listing · 🇺🇸 United States

Compare

15.86

+4.34%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$291.8m

FY2016FY2025

Net income

$554,000

FY2016FY2025

Free cash flow

$27.9m

FY2016FY2025

Shareholders' equity

$13.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$291.8m$203.1m$163.9m$110.2m$49.6m$2.7m$2.7m$2.5m$1.6m$1.1m
Gross profit$238.4m$166.2m$135.3m$87.6m$36.3m$1.1m$1.1m$2.4m$1.6m$1.1m
Research and development$31.2m$25.6m$22.3m$21.0m$25.2m$60.4m$60.4m$40.7m$20.2m$10.2m
Operating income$24.9m−$29.3m−$41.6m−$83.3m−$115.9m−$118.9m−$122.4m−$59.1m−$26.6m−$13.2m
Net income$554,000−$54.8m−$62.3m−$94.7m−$122.7m−$125.6m−$125.6m−$60.1m−$26.6m−$13.2m
Diluted earnings per share0.00-0.37-0.45-0.70-1.01-2.35-4.65-2.89-12.86-2.29

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$383.5m$323.1m$322.6m$344.5m$304.4m$109.0m$109.0m$120.0m$45.0m$33.5m
Cash and short-term investments$111.0m$71.6m$72.5m$122.0m$102.4m$75.5m$75.5m$112.6m$42.0m$32.3m
Total liabilities$369.8m$352.7m$329.4m$299.3m$209.1m$94.6m$94.6m$44.6m$102.8m$65.5m
Debt$220.3m$232.1m$190.9m$187.1m$88.1m$87.0m$58.3m$31.9m——
Shareholders' equity$13.7m−$29.6m−$6.8m$45.2m$95.2m$14.4m$14.4m$75.4m−$57.8m−$31.9m
Shares outstanding180m149m138m136m122m54m27m21m2m6m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$28.6m−$37.0m−$47.0m−$102.9m−$95.5m−$80.6m−$104.3m−$56.3m−$24.7m−$16.1m
Capital spending−$696,000−$868,000−$2.3m−$524,000−$1.1m−$377,000−$1.1m−$1.5m−$700,000−$35,000
Free cash flow$27.9m−$37.8m−$49.3m−$103.4m−$96.6m−$80.9m−$105.5m−$57.8m−$25.4m−$16.1m
Dividends paid———−$147.1m−$25.1m−$95.6m−$60.7m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$92.1m$83.1m$85.8m$74.4m$71.5m$60.1m$60.1m$54.3m
Gross profit$79.6m$69.8m$66.7m$63.4m$56.9m$51.4m$50.6m$40.7m
Operating income$5.2m$7.9m$16.8m$6.7m$4.5m−$3.1m$1.7m−$12.5m
Net income−$31.1m$2.2m$11.1m$621,000−$1.9m−$9.2m−$5.1m−$15.7m
Diluted earnings per share-0.180.010.060.00-0.01-0.05-0.03-0.11
Cash from operations$8.0m$9.0m$20.0m$18.0m—−$10.0m$1.0m−$8.0m
Total assets$411.9m$392.0m$383.5m$370.2m$334.7m$315.5m$323.1m$321.1m
Cash and short-term investments$121.7m$111.8m$111.0m$91.6m$59.3m$58.4m$71.6m$69.4m
Debt$258.9m$227.5m$226.6m$225.7m$224.8m$235.9m$238.2m$237.3m
Shareholders' equity−$9.7m$13.0m$13.7m−$861,000−$19.3m−$35.1m−$29.6m−$28.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue38.3%154.7%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin81.8%81.6%81.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings—-9.2-5.2-1.9-2.9-2.1-0.8-3.0
Price to sales4.82.52.01.67.296.735.873.4

Share price return

Finished calendar years

20252024202320222021202020192018
Return116%59%61%-49%-52%34%-52%-22%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.